NEVY Awards Winner – “Emerging MedTech Company of the Year”
Last night the New England Venture Capital Association (NEVCA) honored the winners of its ninth annual NEVY Awards, recognizing and celebrating the top innovators, investors and companies in the region. The theme this year highlighted the “heroes” of New England’s innovation ecosystem — the entrepreneurs and investors committed to leveraging science and technology for a better tomorrow. We’re honored to receive the recognition for “Emerging MedTech Company of the Year” among Boston’s top startups and late-stage companies at the 9th annual NEVY Awards! 💥A big thank you to the New England Venture Capital Association and their Academy members for the recognition and a shoutout to our team 🦸🏻♀️🦹 that made this win possible.
Read More about NEVY Awards Winner – “Emerging MedTech Company of the Year”
PanTher Therapeutics Doses First Two Patients in Phase 1 Trial of PTM-101 for Treatment of Pancreatic Cancer
PanTher announced today the dosing of the first two patients in its Phase 1 clinical trial of PTM-101 for the treatment of pancreatic cancer. This first-in-human trial will evaluate feasibility, safety, and pharmacokinetics of PTM-101 when used as part of a standard procedure for treatment of patients with locally advanced pancreatic adenocarcinoma. “Launching the PTM-101 Phase 1 trial signals a major step toward our goal of improving therapeutic options for patients with difficult-to-treat solid tumors,” said Laura Indolfi, PhD, Chief Executive Officer of PanTher Therapeutics. “We are thrilled to partner with Dr. Charles Pilgrim and his team at The Alfred Hospital in Melbourne as we incorporate PTM-101 into the treatment for patients with locally advanced pancreatic cancer.”
Read More about PanTher Therapeutics Doses First Two Patients in Phase 1 Trial of PTM-101 for Treatment of Pancreatic Cancer
Becoming A Clinical-Stage Biotech (Requires login)
Life Science Leader’s October 2019 issue featured Laura Indolfi, CEO and co-founder of PanTher Therapeutics, in an article titled “Program Winners Look Back On Year Of Change.” Her company, which makes minimally invasive implantable devices that deliver direct, localized, and sustained cancer therapy to solid tumors, won the first Massachusetts Next Generation Initiative (MassNext-Gen), a competitive program to support women entrepreneurs in early-stage life sciences companies. In June of 2021, PanTher closed an oversubscribed $5.4M Series A round, which set the stage for the company’s first clinical trial. Life Science Leader asked her to share some of her learnings from this key milestone and from the company’s decision to expand its board.
Read More about Becoming A Clinical-Stage Biotech (Requires login)
PanTher Therapeutics Receives Ethics Approval to Initiate Phase 1 Clinical Trial of PTM-101 in Australia
PanTher announced today that it received approval from the Human Research Ethics Committee (HREC) to open a Phase 1 clinical trial of PTM-101 in Australia. PTM-101 is being developed for the treatment of pancreatic cancer. The company also announced today the appointment of J. Marc Pipas, MD, as Chief Medical Officer and the establishment of its clinical advisory board. Dr. Pipas, a veteran GI oncologist and clinical trialist who has assisted in the development of multiple oncology agents from Phase 1 trials through commercialization (including ONIVYDE®, which received approval from the FDA for pancreatic cancer and was subsequently sold to Ipsen Pharmaceuticals for $1 billion), will direct PanTher’s clinical development programs.
Read More about PanTher Therapeutics Receives Ethics Approval to Initiate Phase 1 Clinical Trial of PTM-101 in Australia
PanTher Therapeutics Closes Oversubscribed $5.4M Series A Round, Expands Board of Directors, As Company Prepares to Initiate First Clinical Trial of Novel Localized Treatment of Pancreatic Cancer
PanTher announces today that it has closed an oversubscribed $5.4M Series A round led by Catalyst Health Ventures (CHV), with participation by Angel Physicians Fund (APF) and other notable investors. The Series A round brings the total amount raised by the company to $7.4M. Proceeds from the funding will go toward the company’s first-in-human clinical trial. The company also announced today the additions of Darshana Zaveri, Managing Partner at CHV, Manish Bhandari, Managing Partner at APF, and Maria Palasis, President and CEO of Lyra Therapeutics, to its board of directors. “PanTher represents a truly new therapeutic modality that has the potential to change the way we deliver lifesaving drugs to tumors,” noted Zaveri.
Read More about PanTher Therapeutics Closes Oversubscribed $5.4M Series A Round, Expands Board of Directors, As Company Prepares to Initiate First Clinical Trial of Novel Localized Treatment of Pancreatic Cancer
Inside the Cambridge Biotech Boom
The PanTher Therapeutics team was included in a new documentary about the transformation of an unassuming neighborhood into the innovation and biotechnology ‘capital of the world’. Once shuttered manufacturing plants and vacant parking lots are now home to hundreds of biotechnology companies, nearly all the world’s major pharmaceutical firms, millions of square feet of lab space, tech giants from Google and Microsoft to Facebook and Twitter, and countless startups. And revolutionary, lifesaving therapies and drugs developed here have affected the lives of billions of people across the globe. Join us for the inside story of the rise of one of the world’s most extraordinary innovation clusters – a community now on the front lines of the battle against Covid-19.